A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 27 Feb 2024
At a glance
- Drugs Canagliflozin (Primary)
- Indications Cardiovascular disorders; Myocardial infarction; Stroke; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms CANVAS
- Sponsors Janssen Research & Development; Janssen-Cilag
- 22 Feb 2024 Results of post ho analysis, assessing the potential heterogeneity in cardiovascular (CV), renal and safety outcomes of canagliflozin between Whites and Asians, as well as these outcomes in each subgroup, published in the Diabetes, Obesity and Metabolism
- 04 Jan 2024 Results of pooled analysis from CANVAS Program and CREDENCE assessing Treatment effect of canagliflozin for patients on therapy for heart failure, published in the International Journal of Cardiology
- 30 Nov 2023 Results of pooled analysis assessing effects of canagliflozin on clinical outcomes and intermediate markers of subgroups according to population-specific BMI , from the NCT01032629, NCT01989754 and NCT02065791 studies published in the Diabetes, Obesity and Metabolism.